Storage and handling
Store at 20°-25°C (68°-77°F) with excursions between 15°-30°C (59°-86°F) and protect from light.
Store at 20°-25°C (68°-77°F) with excursions between 15°-30°C (59°-86°F) and protect from light.
For use in horses for correction of conditions associated with low circulating thyroid hormone (hypothyroidism).
The suggested initial dose is 0.5 to 3.0 mg levothyroxine sodium (T-4) per 100 lbs of body weight (1 to 6 mg per 100 kg) once per day or in divided doses. Response to the administration of ThyroKare Powder should be evaluated clinically until an adequate maintenance dose is established. In most horses, the total daily dose of T-4 is in the range of 6 to 36 mg. Serum T-3 and T-4 values can vary greatly among inidividual horses on thyroid supplementation. Dosages should be individualized and animals should be monitored daily for clinical signs of hyperthyroidism or hypersensitivity.
Administration:
ThyroKare Powder can be administered by mixing the daily dose in the concentrate or by top dressing on the grain, preferably rolled or ground. To facilitate the proper adhesion of ThyroKare Powder to the ration, slightly moisten the grain with water or a liquid supplement.
Store at 20°-25°C (68°-77°F) with excursions between 15°-30°C (59°-86°F) and protect from light.
Administer with caution to animals with clinically significant heart disease, hypertension, or other complications for which a sharply increased metabolic rate might prove hazardous. Use in pregnant mares has not been evaluated.
Lot No.:
Exp. Date:
Manufactured by:
Neogen Corporation
Lexington, KY 40511
859-254-1221 or 800-621-8829
animalsafety.neogen.com
Made in USA
NDC: 59051-9128-9
ThyroKare™ Equine Powder
Levothyroxine Sodium USP
(0.22%)
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
NEOGENVet
Net Contents: 10 lb (4.536 kg)
L3396-0816
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1423483 | levothyroxine sodium 1 GM in 453.6 GM Oral Powder | PSN | 1 |
| 2100023 | ThyroKare 0.22 % Equine Powder | PSN | 1 |
| 2100023 | levothyroxine sodium 0.0022 MG/MG Oral Powder [ThyroKare] | SBD | 1 |
| 1423483 | levothyroxine sodium 0.0022 MG/MG Oral Powder | SCD | 1 |
| 1423483 | levothyroxine sodium 0.22 % Oral Powder | SY | 1 |
| 2100023 | ThyroKare 0.0022 MG/MG Oral Powder | SY | 1 |
| 2100023 | ThyroKare 1 GM per 453.6 GM Oral Powder | SY | 1 |
| Class | Version | Type | Effective |
|---|---|---|---|
| LEVOTHYROXINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 97c252d3-9bb8-4530-bb44-9824dc7cf556 | Product name | 6 | 20250729 |
| 6c43b71c-35e6-4db3-ba24-c6ef42ff7003 | Product name | 3 | 20240207 |
| 890fd4bf-1a80-42b7-be1b-2d0259d5f0c8 | Product name | 5 | 20240207 |
| c8ad26bf-af73-460b-b74e-1eff16cc4f9f | Product name | 5 | 20240207 |
| 01383843-4069-43cf-aa76-dc17a6f9f8c4 | Product name | 2 | 20230123 |
| 978cca7d-a938-4791-8322-da48d90a63ef | Product name | 1 | 20230113 |
| 65f86ba3-8816-4e12-899b-18290c8de551 | Product name | 2 | 20210614 |
| f16ab90f-08c2-40be-a543-66d9827cd1f3 | Product name | 1 | 20210601 |
| 6a33ec05-2ae2-45e5-ab82-2d94b3303923 | Product name | 1 | 20190709 |
| 93355a10-1c44-4c92-a11d-7d995e0200d9 | Product name | 1 | 20190219 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 59051-9128-9 | ThyroKare | 4536 g in 1 PAIL | Powder | 4536 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 59051-9128 | THYROKARE (LEVOTHYROXINE SODIUM) POWDER [NEOGEN CORPORATION-MERCER RD] | 1 | 1 package rows | 20181102_f200780c-8532-43e3-bc97-c901ebddb1da.zip |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 59051-9128 | 59051-9128-9 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LEVOTHYROXINE SODIUM | 9J765S329G | ACTIR |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | REMEDYREPACK INC. | bc9385d0-5c67-4bde-94da-e621347e2cba | 2026-09-10 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | REMEDYREPACK INC. | 4c903249-69e9-4168-a9d1-22e6c2c1eb22 | 2026-09-10 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | REMEDYREPACK INC. | 6f25cbb3-0358-4778-b8f0-f76479a2dcc5 | 2026-09-10 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | REMEDYREPACK INC. | 7fd988be-ab3d-406d-a55d-1e5a8a2101cc | 2026-09-10 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine sodium | LEVOTHYROXINE SODIUM | REMEDYREPACK INC. | 6108759a-783e-42ca-b078-6a3cd84ce901 | 2026-09-10 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | REMEDYREPACK INC. | 13e03769-9a4f-497f-9afa-95bf525090b3 | 2026-09-09 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | NorthStar RxLLC | 58f4dc90-3648-49dc-a7e1-baf918a773b5 | 2026-08-20 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NuCare Pharmaceuticals, Inc. | 597ea445-d926-adc6-e063-6394a90a6446 | 2026-08-20 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Coupler LLC | 55f4c679-86cb-b97f-e063-6294a90ad5ef | 2026-07-06 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Coupler LLC | 55f67831-4680-edbf-e063-6294a90a1d36 | 2026-07-06 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 489ffba8-983e-478f-8f62-fe08bf3d0e0b | 2026-06-23 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Coupler LLC | 544d67eb-8487-cb5d-e063-6394a90a3110 | 2026-06-15 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| levothyroxine sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 3b282e57-1009-4d2c-8ca2-9cca9f791937 | 2026-06-12 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Coupler LLC | 53e84179-fe2a-5696-e063-6394a90a8566 | 2026-06-10 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| LEVOTHYROXINE SODIUM | LEVOTHYROXINE SODIUM | Coupler LLC | 5383a4d8-319a-5bf6-e063-6294a90a5497 | 2026-06-05 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | NCS HealthCare of KY, LLC dba Vangard Labs | abe173cc-1579-43a5-b12d-a31958d0a539 | 2026-06-04 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Cardinal Health 107, LLC | 66a3bd4a-770b-4f67-bfa7-6d5e23f2ecbf | 2026-06-04 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Coupler LLC | 53316e75-9897-4935-e063-6294a90a94cf | 2026-06-01 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | Bryant Ranch Prepack | 5852d874-1ebc-49ff-b6c2-1dd513fca784 | 2026-05-27 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
| Levothyroxine Sodium | LEVOTHYROXINE SODIUM | A-S Medication Solutions | c8ae9dc4-836f-4912-80d7-684fd374f40a | 2026-05-27 | Boxed warning, Warnings, Adverse reactions | LEVOTHYROXINE SODIUM |
Adverse event summaries are temporarily unavailable. Other product information remains available.